LRRK2 en LCR: Un biomarcador para una progresión más lenta de la disfunción autonómica en la enfermedad de Parkinson...

The pathophysiological biomarkers underlying the progression of autonomic dysfunction in Parkinson's disease (PD) are not fully understood. We conducted a cohort analysis of 116 sporadic PD patients to determine whether CSF concentrations of total LRRK2 protein and its phosphorylated substrate p-Rab10 predict the trajectories of SCOPA-AUT scores over five years. CSF LRRK2 and p-Rab10 were similarly elevated in sporadic PD and LRRK2 mutation carriers compared with controls. In linear mixed-effects models, higher baseline CSF LRRK2 levels were associated with attenuated annual SCOPA-AUT progression (Ln LRRK2 * time interaction: β = -0.714 points/year; p = 0.003), whereas the interaction between Ln p-Rab10 and time was not significant. These findings indicate that CSF LRRK2 may serve as a biomarker for the progression of autonomic dysfunction in sporadic PD.